Scientists develop injection for long-lasting contraceptive implant
Current contraceptive implants last for years, meaning women do not have to take a pill every day, but the devices must be fitted by a trained professional via a small surgical procedure. Contraceptive injections are already available but they have limitations, including that they last for only three months.
Now scientists say they have completed proof-of-concept experiments for a new type of long-lasting implant that self-assembles in the body.
While not yet tested in humans, the researchers behind the work say the approach could bring benefits beyond the field of birth control, offering a simple way to administer long-acting drug delivery systems without the need for invasive procedures – an appealing prospect for parts of the world with poor medical infrastructure.
'It's suitable for any poorly soluble hydrophobic drug, especially where long-acting delivery is needed. This includes treatments for HIV, TB, schizophrenia, chronic pain, or metabolic disease,' said Dr Giovanni Traverso, a co-author of the study from the Massachusetts Institute of Technology and a gastroenterologist at Brigham and Women's hospital in the US.
The approach involves injecting micro-crystals of a synthetic version of the hormone progesterone contained in a solvent that does not mix well with water.
Once in the body, the solvent exchanges with bodily fluid. However, the micro-crystals prefer to clump together than interact with this water-rich environment. This, together with the formation of further crystals as the solvents exchange, results in the development of a solid implant, capable of releasing the drug slowly over time.
The team, whose study was published in the journal Nature Chemical Engineering, tested the approach in rats, allowing them to refine the choice of solvent in the injection. The drug release in rats was sustained for at least 97 days, although Traverso said there was potential for longer durations depending on formulation adjustments.
'The dosing and volumes of drug are compatible with multi-year dosing,' he said, adding that the formation of a solid implant means it can be removed if required, while the approach is also compatible with the use of small needles.
However, the research is still in its early stages, with the efficacy of the approach yet to be tested. 'It lays the groundwork for future human studies which we hope will start in the next three to five years,' Traverso said.
Dr Janet Barter, the president of the Faculty of Sexual and Reproductive Healthcare, said the approach could be an exciting advancement.
'This innovation has the potential to be convenient option for individuals in low-resource settings, where access to contraception and healthcare services can be limited,' she said. 'We welcome further research into the safety, efficacy, and the accessibility of this promising technology and encourage the authors to work with potential users in future to ensure they meet the needs and preferences of those who will rely on it.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
STV News
a day ago
- STV News
AI designs drugs to combat gonorrhoea and MRSA
Artificial intelligence has helped researchers to design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA. A team at Massachusetts Institute of Technology used AI algorithms to design more than 36 million possible compounds and screen them for antimicrobial properties. The top candidates appeared to be different from any existing antibiotics, and researchers say they work through mechanisms that disrupt bacterial cell membranes. The use of AI allowed scientists to generate and test compounds that had never been seen before. Senior author of the study Professor James Collins said the team is 'excited' about the new possibilities opened up by this project. 'Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,' he said. The team used generative AI algorithms to design molecules based on a specific chemical fragment that showed antimicrobial activity, but they then also let the algorithms freely generate molecules that didn't require that specific fragment. Bacterial resistance to many antibiotics is also increasing – nearly five million deaths each year are caused by drug-resistant bacterial infections. 'We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way,' lead author Aarti Krishnan said. 'By venturing into underexplored areas of chemical space, our goal was to uncover novel mechanisms of action.' It is rare that new antibiotics are discovered and later approved by health authorities. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
Daily Mail
a day ago
- Daily Mail
Prince Harry's former charity Sentebale slashes UK staff to just ONE amid donations collapse and toxic infighting
The charity founded by Prince Harry has laid off all but one of its London staff amid ongoing funding concerns. Sentebale, an HIV /Aids awareness charity, was plunged into crisis earlier this year following a very public feud between the Duke of Sussex and the charity's chairwoman Dr Sophie Chandauka. Four of the five employees based in the organisation's London office have now been made redundant, including its global head of finance and compliance, the Times reports. Last night Sentebale confirmed to the Daily Mail that there is now only one full-time staff member operating at its UK headquarters. They added that 'between April and September there will be a total of seven departures across three locations'. A redundancy letter, sent to staff in April and seen by The Times, stated that the group 'does not have' donor funding and that it is in 'retrenchment'. Harry set up Sentebale with Prince Seeiso of Lesotho in 2006 to work with disadvantaged young people in Lesotho and Botswana, with both men honouring their late mothers. But the pair stepped away from the charity this month following a damning report into an explosive race row sparked by Dr Chandauka. The UK Charity Commission had launched a probe into the acrimonious boardroom battle - but criticised both sides in its findings. The probe said it could find 'no evidence' of 'widespread or systemic bullying or harassment, including misogyny or misogynoir' at Sentebale after Dr Chandauka made a series of incendiary allegations about the behaviour of the Duke of Sussex and his fellow trustees. But it also criticised the trustees, who included Harry, who resigned en masse in March after the row was made public. Scores of donors - loyal to the Duke and Duchess of Sussex - allegedly stopped donating to the charity, costing hundreds of thousands of pounds in essential funding. The watchdog acknowledged the 'strong perception of ill treatment' felt by all parties, including Dr Chandauka, and the impact this may have had on them. It ruled that failures leading up to, and following, the dispute had led to 'mismanagement in the administration of the charity'. A Sentebale spokesperson said the charity had 'suffered from the negative impact of the adverse media campaign launched by the duke and former trustees on 25 March'. In a sign the two parties remain deeply entrenched, they added that this was as a result of the Charity Commission probe 'which has made fundraising extremely challenging for Sentebale and so we have been reliant on reserves'. The spokesperson told the Daily Mail: 'First discussed in 2024, the Sentebale Board took a deliberate and responsible step to right-size its workforce in all three locations due to increasing uncertainty relating to international donor funding such as USAID and uncertainty relating to events such as polo.' The Senetable Polo Cup - which historically raised around £740,000 a year - has not taken place for the last two years. The spokesperson added: 'The global restructuring was intended to improve efficiencies, transition senior executive roles to Southern Africa and to respond to changing service delivery demands. 'False is the notion that any restructuring was because of a 'funding crisis', but was a planned restructuring.'
ITV News
2 days ago
- ITV News
AI designs drugs to combat gonorrhoea and MRSA
Health Antibiotics Science Artificial intelligence has helped researchers to design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA. A team at Massachusetts Institute of Technology used AI algorithms to design more than 36 million possible compounds and screen them for antimicrobial properties. The top candidates appeared to be different from any existing antibiotics, and researchers say they work through mechanisms that disrupt bacterial cell membranes. The use of AI allowed scientists to generate and test compounds that had never been seen before. Senior author of the study Professor James Collins said the team is "excited" about the new possibilities opened up by this project. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,' he said. The team used generative AI algorithms to design molecules based on a specific chemical fragment that showed antimicrobial activity, but they then also let the algorithms freely generate molecules that didn't require that specific fragment. Bacterial resistance to many antibiotics is also increasing - nearly five million deaths each year are caused by drug-resistant bacterial infections. "We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way," lead author Aarti Krishnan said. "By venturing into underexplored areas of chemical space, our goal was to uncover novel mechanisms of action." It is rare that new antibiotics are discovered and later approved by health authorities.
